Enterocyte

Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May

Retrieved on: 
Mittwoch, April 10, 2024
Cholecalciferol, LDL, CRM, Cholesterol, Cardiovascular disease, Medicine, Digital, Dietary supplement, Business, Risk, Patient, Pharmacy, DSM-IV codes, ERP, Research, Stroke, Pharmacist, Business development, Executive Committee, HEART, Artery, Research and development, Omega-3 fatty acid, Safety, Enterocyte, Lipid metabolism, General practitioner, Marketing, Practitioner, Sleep, Hypercholesterolemia, Pharmaceutical industry

The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."

Key Points: 
  • The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."
  • Available behind the counter in pharmacies, the dietary supplement will also be sold without a prescription with a pharmacist’s recommendation.
  • It comprises a new generation of dietary supplements with active ingredients of natural origin, acting on several targets for comprehensive management.
  • A principal mechanism controls intestinal cholesterol absorption, while a complementary mechanism acts on hepatic metabolism for a comprehensive approach to the management of hypercholesterolemia.

Rebamipide May Combat Low-Grade Inflammation in Post-COVID-19 Syndrome Patients

Retrieved on: 
Montag, Februar 19, 2024
Group 1, Coronavirus, AAAAI, Research, SARS-CoV-2, Doctor of Philosophy, Multimedia, Inflammation, Nonsteroidal anti-inflammatory drug, Enterocyte, Asthma, ELISA, Radical, Arthralgia, Group 2, COVID-19, CRP, COVID, Patient, Journal, Rehabilitation, Plasma, Ageing, Rebamipide, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC, this month.

Key Points: 
  • "This study revealed higher levels of lipopolysaccharide-binding protein, and lower levels of bacterial permeability protein in patients with post COVID syndrome.
  • Rebamipide, by reducing intestinal permeability, reduces endotoxin load, lowering the level of low-grade inflammation.
  • To explore Rebamipide's usefulness for rehabilitating SARS-CoV-2 post-COVID syndrome patients, researchers examined 62 patients, aged 42-55 years with post-COVID-19 syndrome using nonsteroidal anti-inflammatory drugs for joint pain.
  • Given the effects of SARS-CoV-2 on enterocytes, the results suggest that Rebamipide may be useful for rehabilitation of patients with SARS-CoV-2 post-COVID syndrome.

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Dienstag, November 14, 2023
NDA, Cisplatin, Disclosure, Galera, Chronic kidney disease, Annual general meeting, Superoxide dismutase, ASN, ASTRO, Food, Type, SBRT, Head, Incidence, Investment, New Drug Application, Clinical trial, American Society of Nephrology, Insurance, Patient, Workforce, Research, Radiation therapy, Death, FDA, CKD, Neoplasm, LAPC, Therapy, Manganese, Enterocyte, GRECO, Cancer, CRL, Symantec Endpoint Protection, Combination, Superoxide dismutase mimetics, Layoff, Society, HNC, Poster, Pharmaceutical industry

MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.

Key Points: 
  • The Company is exploring potential strategic alternatives, as it is not feasible to conduct an additional trial with the Company’s current resources.
  • Research and development expenses were $6.1 million in the third quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $5.0 million in the third quarter of 2023, compared to $4.9 million for the same period in 2022.
  • As of September 30, 2023, Galera had cash, cash equivalents and short-term investments of $28.4 million.

EQS-News: Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Retrieved on: 
Samstag, Mai 6, 2023
Molecule, Paneth cell, Gastrointestinal disease, Histology, Diarrhea, Gastrointestinal tract, Epithelium, Biotechnology, Clinical trial, Irritable bowel syndrome, Biomarker, Ulcerative colitis, DDW, Regeneration, Enterocyte, Patient, Action, Poster, B cell, Coeliac disease, DSS, Vaccine, Pharmaceutical industry, Paneth, Short course immune induction therapy, SIRT6

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Key Points: 
  • Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
    The issuer is solely responsible for the content of this announcement.
  • The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.
  • In both animal and early clinical studies, IMU-856 has been shown to restore and renew the intestinal lining.
  • Immunic reported that IMU-856 treatment showed beneficial effects in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Retrieved on: 
Samstag, Mai 6, 2023
Molecule, Paneth cell, Histology, Diarrhea, Gastrointestinal tract, Epithelium, Clinical trial, Irritable bowel syndrome, Biomarker, Ulcerative colitis, DDW, Crohn's disease, Regeneration, Enterocyte, Patient, Poster, B cell, Coeliac disease, Phenotype, DSS, Pharmaceutical industry, Vaccine, Paneth, Short course immune induction therapy, SIRT6

NEW YORK, May 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of clinical and preclinical data for IMU-856. Included in this presentation are new data on IMU-856's mode of action as a potent modulator of SIRT6 (Sirtuin 6), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.

Key Points: 
  • The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.
  • In both animal and early clinical studies, IMU-856 has been shown to restore and renew the intestinal lining.
  • Immunic reported that IMU-856 treatment showed beneficial effects in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.
  • That said, we are preparing for a phase 2b clinical trial of IMU-856 in celiac disease patients, while also considering other indications."

Oil-Dri Receives Brazilian Patent for Mineral-Based Feed Additive Formulation Used in Poultry and Swine Antibiotic-Free Production

Retrieved on: 
Dienstag, August 2, 2022
GLOBE, Peanut Corporation of America, Bittiolum varium, Enterocyte, ODC, Prizes as an alternative to patents, NYSE, Government, VP, Health, New, Traction, Patent, Poultry, ABF, Meat, Efficiency, Poultry Products Inspection Act of 1957, Growth, Animal, Miniature pig

The patent protects the novel, mineral-based formulation used in Amlan Internationals existing natural feed additives, Varium for poultry and NeoPrime for swine, that provide swine and poultry producers with natural solutions to optimize intestinal health and add value to their operations.

Key Points: 
  • The patent protects the novel, mineral-based formulation used in Amlan Internationals existing natural feed additives, Varium for poultry and NeoPrime for swine, that provide swine and poultry producers with natural solutions to optimize intestinal health and add value to their operations.
  • Varium and NeoPrime are sold and marketed in select international markets by Amlan, the animal health business of Oil-Dri.
  • Changing regulations from the countries that import Brazilian poultry meat have created a market pull for antibiotic-free (ABF) poultry production in Brazil.
  • Product availability may vary by country; associated claims do not constitute medical claims and may differ based on government requirements.